menu

CME: When Insulin Isn’t Enough: Exploring Dual SGLT1 and SGLT2 Inhibition in T1DM

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

When Insulin Isn’t Enough: Exploring Dual SGLT1 and SGLT2 Inhibition in T1DM

When Insulin Isn’t Enough: Exploring Dual SGLT1 and SGLT2 Inhibition in T1DM
RestartResume
This patient-clinician panel discussion provides unique perspectives on the treatment and management of Type 1 Diabetes.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This activity explores new and emerging treatments for type 1 diabetes, including a dual sodium glucose transporter 1/2 inhibitor, and provides both clinician and patient perspectives on their use.

  • Learning Objectives

    • Explain the mechanism of action involved in dual inhibition of SGLT1 and SGLT2 and the rationale for this approach (versus SGLT2 inhibition alone) in T1DM
    • Summarize key efficacy and safety data on dual SGLT1 and SGLT2 inhibition in T1DM
  • Target Audience

    This educational activity is intended for primary care providers and endocrinologists.

  • Faculty Disclosures

    Anne Peters, MD, has served as a non-CE consultant for Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Company, Lexicon, Livongo, Medscape, Merck, Novo Nordisk, OptumHealth and Sanofi US. She has received research support from AstraZeneca, Dexcom and Mannkind. Dr. Peters has an ownership interest/stock options with Mellitus Health, Omada Health and Stability Health.

    Donna Miller, MSN, FNP-C, CDE, has nothing to disclose.

    Jana Conley has nothing to disclose. 

  • Accreditation and Credit Designation Statement

    The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

  • Commercial Support

    Supported by an educational grant from Sanofi and Lexicon Pharmaceuticals.

  • Terms of Use

    The France Foundation (TFF) requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

  • Method of Participation/How to Receive Credit

    1. Review the activity objectives and CME/CE information.
    2. Complete the CME/CE activity.
    3. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
    4. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Disclaimers

    The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation assumes no liability for the information herein.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00

    You must be in to display playlists.

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.